The REPAIR Impact Fund’s 2022 global call is open for investment proposals now and closes on 7 May. Our philosophy is to support ambitious programmes addressing antimicrobial resistance through a broad range of therapeutic modalities.
The first-pass selection priorities will be based on a non-confidential presentation. Companies given priority will then be invited to send a full business plan with an extended presentation of the scientific rationale, available data, budget and development plan, including milestones, to be reviewed by our Scientific Selection Board. Based on the assessment of the Scientific Selection Board, including a question-and-answer process, the finalists will be nominated and invited to present their projects live to the Scientific Selection Board.
- Pathogens: from the high-priority list of the World Health Organization and the United States Centers for Disease Control and Prevention
- Therapies: first-in-class therapies have priority
- Modalities: small molecules, biologics and new modalities
- Phases: from the early stage of drug development (lead optimization) to the early stages of clinical development (Phase 1)
Learn more here. REPAIR Impact Fund · Investment Process (repair-impact-fund.com)